Related Experiment Video
Updated: May 26, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and
Sunyana Gadal1, Jacob A Boyer2, Simon F Roy3,4
1Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.
BRAF V600E mutations promote cell proliferation but inhibit migration. Secondary mutations are required for melanoma development by rescuing this migration defect, highlighting potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- BRAF V600E mutations are common in melanoma, driving proliferation via ERK signaling.
- However, BRAF V600E alone is insufficient for melanoma development, as it also occurs in benign nevi.
Purpose of the Study:
- To investigate why BRAF V600E mutations do not always lead to melanoma.
- To identify mechanisms by which melanoma progresses despite BRAF V600E-induced signaling.
Main Methods:
- Utilized genetically engineered mouse models and human benign nevi/melanoma samples.
- Analyzed the impact of BRAF V600E on cell migration and signaling pathways (ERK, RAC1).
- Investigated the role of secondary mutations (RAC1, PTEN) in restoring cell motility.
Main Results:
- BRAF V600E inhibits mesenchymal migration through feedback inhibition of RAC1 activity.
- ERK pathway inhibition or secondary mutations (mutant RAC1, PTEN inactivation) restore RAC1 activity and cell migration.
- These rescuing mutations are present in 26% of BRAF V600E-mutated melanomas.
Conclusions:
- BRAF V600E-driven ERK signaling deregulates proliferation but hinders malignant transformation by inhibiting RAC1-dependent migration.
- Secondary genetic lesions that rescue this migration defect are essential for melanoma tumorigenesis.
- Oncogenic feedback mechanisms may shape the genetic landscape of tumors, selecting for mutations that are potential therapeutic targets.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
Related Concept Videos
The Ras Gene
Ras is a...
Cancers Originate from Somatic Mutations in a Single Cell
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer Cell Migration through Invadopodia
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...